CML-415 Treatment Free Remission (TFR) in Chronic Myeloid Leukemia-Chronic Phase (CML-CP), Kuwait Experience

Alhuraiji, Ahmad; Hasaneen, Mahmoud; Hassanein, Mona; Mohan, Ram; Khadadah, Fatima; Kunhikrishnan, Anita; Shah, Abdul Rashid; Hamadah, Abdulaziz; Alshemmari, Salem; Pandita, Ramesh

doi:10.1016/s2152-2650(22)01382-9

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te median total time on TKI for our cohort was almost 1.5 to 4-fold more than the recommended minimum total period on TKI as per guidelines before discontinuation of TKI [21][22][23][24][25], which may also be the reason for the higher rate of success in our cohort. Te cumulative period on TKI has been shown to be one of two strong predictors of TFR success [17,18,47]. In a study recently presented at ASCO by the MD Anderson group, Haddad et al [49] noted higher rates of success (79%) for patients who remained in DMR for more than 5 years, which was not noted to be signifcant in our analysis.…”

Section: Discussionmentioning

confidence: 45%

“…Whilst the success rate is superior to those described in landmark studies [16][17][18][19][20] as well as other single-centre studies (Table 1), the follow-up period was notably shorter in our study, at most half the time. Another recently published, single-centre study reported in Kuwait by Alhuraiji et al [47] also noted a high TFR success rate (74%), which they attributed to a prolonged period of DMR (>5 years). Despite the rate of TFR success being 75% at 12 months, and the risk of failing TFR being signifcantly less after 6 months [24], late relapses have been reported [48].…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

The Success of Treatment Free Remission in Chronic Myeloid Leukaemia in Clinical Practice: A Single-Centre Retrospective Experience from South Africa

Hoosen

Mackraj

Rapiti

2023

Advances in Hematology

View full text Add to dashboard Cite

Introduction. Chronic myeloid leukaemia (CML) management has evolved from a disease once considered to be incurable just over 2 decades ago to that of one of a “functional cure” as defined by the sustained molecular response on stopping tyrosine kinase inhibitor(TKI) therapy. The next goal of CML management has been treatment-free remission (TFR). The past 4 years have seen much international data on TFR attempts in CML in clinical practice. However, Africa as a continent has lagged behind the rest of the world, in keeping up with the latest trends in CML management, and so this study aims to address this gap by assessing the outcome of TFR in CML in a single centre in South Africa (SA). Methods. We conducted a retrospective cohort study in 12 CML patients in the chronic phase to assess the success of TKI discontinuation. The patients were treated in King Edward VIII Hospital (KEH), a tertiary, academic hospital in KwaZulu-Natal, South Africa, and the study period was from June 2020 to May 2022. Patients included had to have been on TKI therapy for a minimum of 5 years and achieved a deep molecular response (DMR) for a minimum period of 3 years. Results. The overall TFR cohort showed a success rate of 75% at a median follow-up of 12 months. All patients who failed TFR, defined as a loss of major molecular remission (MMR), failed within 6 months of stopping TKI therapy. All patients who failed TFR regained DMR after retreatment with TKI, with no disease progression reported. The only factor influencing the success of TFR was the total period of TKI therapy. Conclusion. Despite our study having a small cohort of patients, this study demonstrated that TFR in CML is an attainable goal, even in a resource-limited setting.

show abstract